Share

Two Medication Classes Reduced Cardiovascular and Liver Events in People with Type 2 Diabetes

GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data presented at ENDO 2024. Researchers reviewed Medicare data documented from 2013 to 2020 and a large U.S. health insurance database from 2013 to 2022. They performed...
Share

Liraglutide Increases Insulin Sensitivity Independent of Weight Loss, Study Shows

Liraglutide, the glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat type 2 diabetes and obesity, can lead to rapid improvement in insulin sensitivity, according to a study recently published in Diabetes. “We know that GLP-1R agonists promote weight loss, but we were surprised to find that the GLP-1R agonist liraglutide also has rapid effects on...
Share

Researchers Observe Beta-Arrestin’s Mechanism in GPCRs

Beta-arrestins attach themselves to outer cell membranes, waiting for hormones or neurotransmitters to land on receptors – an unexpected and surprising finding recently published in Cell. Researchers led by Davide Calebiro, MD, professor of Molecular Endocrinology in the Institute of Metabolism and Systems Research at the University of Birmingham and Co-Director of the Centre of...

Diabetes Research Articles

Get the most up to date news on diabetes research and treatment. For more information read the latest issue of Endocrine News.